Procedure for Documentation of Formulation Development Process
| Department | Research and Development (R&D)/Quality Assurance |
|---|---|
| SOP No. | FD-020 |
| Supersedes | V 1.0 |
| Page No. | Page X of Y |
| Issue Date | [Insert Issue Date] |
| Effective Date | [Insert Effective Date] |
| Review Date | [Insert Review Date] |
1. Purpose
The purpose of this Standard Operating Procedure (SOP) is to define the standardized approach for documenting the formulation development process of ointments. Proper documentation ensures traceability, compliance with regulatory standards, and consistency in product development.
2. Scope
This SOP applies to the Research and Development (R&D) and Quality Assurance (QA) departments responsible for maintaining detailed records of the formulation development process from concept to finalization.
3. Responsibilities
- Formulation Scientist: Documents all formulation trials and modifications.
- Quality Control (QC) Analyst: Maintains records of analytical data and test results.
- Quality Assurance (QA) Personnel: Reviews and ensures compliance with documentation standards.
- R&D Head: Approves final formulation development reports before scale-up.
4. Accountability
The R&D and QA Managers are accountable for ensuring that all formulation development records are complete, accurate, and compliant with GMP and regulatory requirements.
5. Procedure
5.1 Initiation of Documentation
- Maintain a Formulation Development Record (FDR) for each formulation.
- Assign a unique identification number to each formulation project.
- Record all preliminary research, rationale for ingredient selection, and expected formulation outcomes.
5.2 Recording Formulation Trials
- Document all trial batch compositions, including:
- Active Pharmaceutical Ingredients
(APIs)
Excipients
Preservatives
pH Adjusters
Record batch numbers, quantities, and processing parameters.
Maintain a Formulation Change Log to track any modifications.
5.3 Analytical and Stability Data
- Maintain records of physical, chemical, and microbiological testing.
- Document stability study results at different storage conditions.
- Ensure all analytical data is reviewed and signed off by QC personnel.
5.4 Scale-Up Feasibility Assessment
- Document critical process parameters (CPPs) and critical quality attributes (CQAs).
- Assess reproducibility and prepare a Scale-Up Justification Report.
5.5 Approval and Final Documentation
- Compile all formulation development documents into a Final Formulation Report.
- Obtain QA and R&D Head approval before initiating commercial batch production.
- Store all documents securely for future reference and regulatory audits.
6. Abbreviations
- FDR – Formulation Development Record
- QC – Quality Control
- QA – Quality Assurance
- API – Active Pharmaceutical Ingredient
- CPP – Critical Process Parameter
- CQA – Critical Quality Attribute
7. Documents
- Formulation Development Record (Annexure-1)
- Formulation Change Log (Annexure-2)
- Scale-Up Justification Report (Annexure-3)
- Final Formulation Report (Annexure-4)
8. References
- ICH Q8(R2) Pharmaceutical Development Guidelines
- WHO GMP Guidelines for Pharmaceutical Manufacturing
- 21 CFR Part 211 – Current Good Manufacturing Practices
9. SOP Version
Version 2.0
10. Approval Section
| Prepared By | Checked By | Approved By | |
|---|---|---|---|
| Signature | |||
| Date | |||
| Name | |||
| Designation | |||
| Department |
11. Annexures
Annexure-1: Formulation Development Record
| Date | Formulation ID | Ingredient Name | Quantity | Processing Parameters | Verified By |
|---|---|---|---|---|---|
| 01/02/2025 | FDR-001 | API-A | 5 g | Heated to 60°C | QA Officer |
| 02/02/2025 | FDR-002 | Emulsifier | 2 g | Mixed for 10 min | QA Officer |
Annexure-2: Formulation Change Log
| Date | Formulation ID | Change Description | Reason for Change | Approved By |
|---|---|---|---|---|
| 01/02/2025 | FDR-001 | Increased emulsifier | Improved stability | QA Head |
| 02/02/2025 | FDR-002 | Adjusted pH | Skin compatibility | QA Head |
Annexure-3: Scale-Up Justification Report
| Date | Formulation ID | Scale-Up Feasibility | Critical Process Parameters | Final Decision |
|---|---|---|---|---|
| 01/02/2025 | FDR-001 | Feasible | Temperature, Mixing Speed | Approved |
Annexure-4: Final Formulation Report
| Date | Formulation ID | Final Composition | Quality Parameters | Approval Status |
|---|---|---|---|---|
| 01/02/2025 | FDR-001 | API, Emulsifier, Preservative | pH, Stability, Microbial | Approved |
12. Revision History:
| Revision Date | Revision No. | Details of Revision | Reason for Revision | Approved By |
|---|---|---|---|---|
| 01/01/2024 | 1.0 | Initial Version | New SOP | QA Head |
| 01/02/2025 | 2.0 | Updated SOP Format | Standardization of Document | QA Head |